<DOC>
	<DOC>NCT02828124</DOC>
	<brief_summary>A Study to Evaluate the Safety and Tolerability of BMS-986183 in Patients with Liver Cancer</brief_summary>
	<brief_title>A Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Must have advanced liver cancer that cannot be treated with surgery or other local methods Liver cancer is confirmed by a microscopic examination of tissue Liver disease is classified as 'A' by a standard method called ChildPugh score Daily living abilities are classified as '0 or 1' by a standard method from the Eastern Cooperative Oncology Group (ECOG) Women must use contraception Prior liver transplant Increase in blood pressure in some of the veins entering the liver Cancer that has spread to the brain or the layers of tissue that cover the brain or spinal cord Disease of the heart or blood vessels around the heart Active cancers within the last 2 years No more than 2 prior systemic treatments or other investigational agents except PD1/PDL1 or Ipilimumab (Part 2) Currently on antiplatelet or anticoagulation therapy Radiotherapy within 4 weeks of treatment Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>